company background image
ANIX

Anixa Biosciences NasdaqCM:ANIX Stock Report

Last Price

US$3.82

Market Cap

US$113.4m

7D

1.3%

1Y

-8.6%

Updated

10 Aug, 2022

Data

Company Financials +
ANIX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ANIX Stock Overview

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases.

Anixa Biosciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Anixa Biosciences
Historical stock prices
Current Share PriceUS$3.82
52 Week HighUS$5.87
52 Week LowUS$2.30
Beta1.53
1 Month Change24.84%
3 Month Change19.38%
1 Year Change-8.61%
3 Year Change-8.61%
5 Year Change479.67%
Change since IPO-95.51%

Recent News & Updates

Jul 21

Anixa to get additional US patent linked to breast cancer vaccine technology

Anixa Biosciences (NASDAQ:ANIX) said the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for a new patent related to the company's breast cancer vaccine technology. The company said the technology has been exclusively licensed from and is being developed in partnership with Cleveland Clinic. The patent is titled 'Breast Cancer Vaccine' and the lead inventor is Vincent Tuohy of the Department of Inflammation and Immunity at Cleveland Clinic's Lerner Research Institute. "This breast cancer vaccine has the potential to prevent Triple Negative Breast Cancer ("TNBC"), the deadliest form of breast cancer, and perhaps other forms of breast cancer that express alpha-lactalbumin," said Anixa Chairman and CEO Amit Kumar.

Jun 13
Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

May 11

Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times

Anixa Biosciences has different very interesting programs ongoing, one of which is a breast cancer vaccine trial with a first partial readout at ASCO in the beginning of June. While the biotech sector has been suffering large losses over the past month, Anixa Biosciences shares have moved up remarkably. Trial enrollment for the vaccine trial was fast, and the company seems optimistic about the near-term future of the company. The market is huge, and if the trial is successful, chances are we are seeing the beginning of a huge spike in share price. 2022 will, in any case, be the year for Anixa, with other programs ongoing as well.

Shareholder Returns

ANIXUS BiotechsUS Market
7D1.3%6.3%0.3%
1Y-8.6%-25.9%-13.5%

Return vs Industry: ANIX exceeded the US Biotechs industry which returned -25.9% over the past year.

Return vs Market: ANIX exceeded the US Market which returned -13.5% over the past year.

Price Volatility

Is ANIX's price volatile compared to industry and market?
ANIX volatility
ANIX Average Weekly Movement10.7%
Biotechs Industry Average Movement12.8%
Market Average Movement7.9%
10% most volatile stocks in US Market17.2%
10% least volatile stocks in US Market3.2%

Stable Share Price: ANIX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: ANIX's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19825Amit Kumarhttps://www.anixa.com

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company’s therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer.

Anixa Biosciences, Inc. Fundamentals Summary

How do Anixa Biosciences's earnings and revenue compare to its market cap?
ANIX fundamental statistics
Market CapUS$113.35m
Earnings (TTM)-US$15.72m
Revenue (TTM)n/a

9,999x

P/S Ratio

-7.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ANIX income statement (TTM)
Revenue-US$500.00
Cost of RevenueUS$2.00
Gross Profit-US$502.00
Other ExpensesUS$15.72m
Earnings-US$15.72m

Last Reported Earnings

Apr 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.52
Gross Margin100.40%
Net Profit Margin3,144,080.00%
Debt/Equity Ratio0%

How did ANIX perform over the long term?

See historical performance and comparison